Retatrutide 40mg
Identity
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.30
Physical form
- Appearance
- White lyophilised powder
- Purity
- 99%+ (HPLC)
- Solubility
- Soluble in bacteriostatic water
Handling
- Storage
- -20C, protected from light
- Shelf life
- 24 months from date of manufacture, sealed
Also known as LY3437943, Triple agonist peptide
£268.00
Triple receptor agonist peptide, 40mg. For extended receptor pharmacology work.
25 in stock
- Dispatch Same day if you order before the cut off, tracked
- Documentation Your batch certificate is emailed when it ships
- Storage -20C, protected from light
Please note: retatrutide is still in clinical development and is not an approved medicine anywhere. We supply it for laboratory research only.
Product description
The 40mg format of the triple receptor agonist peptide, for extended receptor pharmacology work.
Research context
Same compound and context as the 20mg vial. The larger format is for study designs running many conditions, where holding every arm on one lot is worth more than ordering as you go.
Handling notes
Handled identically. Bacteriostatic water, slow addition, gentle swirling, frozen storage, aliquot after reconstitution. Calculate your reconstitution volume against the full 40mg before you open it.
Worth knowing
Also referenced as LY3437943 in the literature.
Documentation
This batch ships with its own certificate of analysis showing HPLC purity and mass spectrometry identity confirmation. The batch reference is recorded against your order, so a result generated months from now can be traced back to this specific lot.
Intended use
Supplied strictly for laboratory research use. Not a medicine. Not for human or veterinary consumption, and not for any diagnostic or therapeutic use.
Research background
The short version
Adds a third receptor to what tirzepatide does. Where tirzepatide acts on two gut hormone receptors, retatrutide acts on three, including the glucagon receptor.
Retatrutide is a synthetic peptide with agonist activity at the GIP, GLP-1 and glucagon receptors. The addition of glucagon receptor activity is what distinguishes it and is the main subject of comparative work against dual agonists.
Where it came from
Developed by Eli Lilly under the code LY3437943. In clinical development rather than approved.
How it is thought to work
Triple agonism, with the glucagon receptor component proposed to contribute through effects on energy expenditure rather than through the appetite pathways associated with GLP-1.
Balancing activity across three receptors is the central design problem, and receptor level characterisation is where most laboratory work sits.
What it is studied for
What the published research found, and what it was tested in. We list the model against each one so you can judge how far the findings go.
- Triple receptor pharmacology Relative potency across GIP, GLP-1 and glucagon receptors. What they found Agonist activity confirmed at GIP, GLP-1 and glucagon receptors, with the balance between the three being the principal design variable. Tested in Receptor binding assays, cell culture
- Comparative studies Set against tirzepatide and against single receptor agonists. What they found Set against tirzepatide in receptor level work, with the glucagon component the main point of difference. Tested in Cell culture, rodent models
- Glucagon receptor contribution Isolating what the third receptor adds. What they found Glucagon receptor activity proposed to contribute through energy expenditure pathways rather than through the appetite pathways associated with GLP-1. Tested in Cell culture
Specification
| CAS number | 2381089-83-2 |
|---|---|
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731.30 |
| Purity | 99%+ (HPLC) |
| Appearance | White lyophilised powder |
| Solubility | Soluble in bacteriostatic water |
| Storage | -20C, protected from light |
| Shelf life | 24 months from date of manufacture, sealed |
What you get
- The vial Retatrutide 40mg. Sealed and labelled with the compound and its batch reference.
- Certificate of analysis For your batch specifically. Emailed when your order ships and available on this page now.
- Cold chain packaging Gel pack and insulation. We ship these early in the week so nothing sits in a depot over the weekend.
- Plain outer packaging Plain on the outside for your privacy. Everything inside is clearly labelled.
How it compares
How this compares to the compounds people usually weigh it against. Only the specs that actually differ are shown.
| Specification | Tirzepatide 30mg | Retatrutide 20mg | This product Retatrutide 40mg |
|---|---|---|---|
| Molecular weight | 4813.53 | 4731.30 | 4731.30 |
| Price | £118.00 | £145.00 | £268.00 |
Questions about this compound
How should Retatrutide 40mg be stored?
Store the sealed vial at -20C, protected from light. Sealed and held at that condition it carries a shelf life of 24 months from date of manufacture, sealed from the date of manufacture. Once reconstituted, shelf life shortens considerably and the solution should be aliquoted before freezing rather than thawed repeatedly.
How is Retatrutide 40mg reconstituted?
Soluble in bacteriostatic water. Add the solvent slowly down the inside wall of the vial rather than directly onto the material, then swirl gently to dissolve. Do not shake, vortex or sonicate to speed it up. A cloudy solution that will not clear usually means the wrong solvent rather than a poor batch.
What purity is this batch and how is it verified?
This item is supplied at 99%+ (HPLC), measured by high performance liquid chromatography. Identity is confirmed separately by mass spectrometry. Both results appear on the certificate of analysis for the batch you receive, not for a previous lot.
Can I see the certificate of analysis before ordering?
Yes. It is linked in the documentation section of this page. If no certificate is shown against this listing, ask before ordering rather than after.
Is Retatrutide 40mg the same as the other names it appears under?
Yes. Retatrutide 40mg also appears in the literature as LY3437943, Triple agonist peptide. They refer to the same compound, which is worth knowing when searching for prior work because results are split across the names.
Can this be used in humans or animals?
No. This is supplied strictly as a laboratory reagent for in vitro research. It is not a medicine, it is not licensed for human or veterinary use, and it should not be administered to a person or an animal. We do not provide dosing or administration guidance.
Handy guides
- Reconstitution and solvents Choosing a solvent, adding it without damaging the peptide, working out concentrations, and the handling errors that cost people a vial.
- Storage and handling Temperature, light, reconstitution and shelf life, and what actually degrades a compound in practice.
- Freeze thaw cycles and shelf life What degrades a peptide in practice, how much a freeze thaw cycle actually costs you, and how to plan aliquots so it stops mattering.
- How to read a certificate of analysis A section by section walkthrough of a peptide certificate: what each figure means, what it does not mean, and the checks worth making before you accept a batch.
